GOSS - Gossamer Bio Inc logo

GOSS

Gossamer Bio Inc

Rev โ€”top 1%5Y
Hold

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib for pulmonary hypertension and GB002, an inhaled small-molecule therapy targeting specific receptors, currently in Phase 3 trials for pulmonary arterial hypertension.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$20today

Score Overview

1 Year
Score
Net Growth-5.88%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth14.58%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth22.91%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend40%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth0.23%
Net Trend57%
Net Income Consistency
Rev Growthโ€”
Rev Trend29%
Revenue Consistency

See the full market ranking โ†’

Gossamer Bio Inc fundamental performance

Across Gossamer Bio Inc's full reported history, from 2019 to 2025, revenue grew from $ 0.00 to $ 48M and net income went from -$ 180M to -$ 170M. Revenue increased in 29% of the years measured; net income in 57%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.18โ€”
1 Year2025-08-12
$ 1.93-90.80%
5 Years2021-08-12
$ 8.81-97.98%
All Time2019-02-08
$ 17.94-99.01%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 55M-$ 180M$ 99M
2025$ 48M-$ 170M$ 136M
2024$ 114M-$ 56M$ 294M
2023$ 0.00-$ 179M$ 296M
2022$ 0.00-$ 229M$ 255M
2021$ 0.00-$ 234M$ 325M
2020$ 0.00-$ 243M$ 512M
IPO2019$ 0.00-$ 180M$ 401M

Explore beyond GOSS

You're looking at Gossamer Bio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies